Stories, research and organisational learning gathered in one place.
Featured resource / Latest News
When the work stopped, TB did not.
When USAID funding for ACCELERATE 1 ended abruptly, years of work bringing TB screening, diagnosis, treatment and prevention closer to vulnerable communities in South Africa’s Eastern Cape came to a sudden halt. Dr Priashni Subrayen reflects on what was lost, what happened to patients and staff, and how an unexpected lifeline allowed a smaller team […]
Dr Phindi Nxumalo Senior Technical Director How Dr P led through one of Aurum’s most challenging periods “We had to think about our staff, our patients and what needed to happen next.” On a Monday morning in January, Dr Phindi Nxumalo, known to colleagues affectionately as Dr P, received a call she will never forget. […]
Aurum Group Chief Operating Officer Prof Vinodh Edward has been named one of Speak Up Africa’s 2025 African Voices of Science (AVoS) Champions, joining a continental cohort of leaders working to strengthen African voices in health research, policy and innovation. Selected from a competitive cohort of health research and development leaders across Kenya, Côte d’Ivoire, […]
Pearl Khwezi visits Aurum’s clinical research site
International Broadway actress Pearl Khwezi recently visited Aurum’s Tembisa Clinical Research Site to learn more about the organisation’s clinical research work. During the visit, Pearl engaged with Aurum’s research teams and explored the work of the Clinical Research Division, including clinical trials and vaccine research. The visit provided an opportunity to see how research is […]
Dr Tonderai awarded NIHR Global Advanced Fellowship
Aurum’s Dr Tonderai Mabuto, Specialist Scientist has been awarded an NIHR Global Advanced Fellowship, recognising his work to strengthen HIV research and health systems across sub-Saharan Africa. The fellowship will support his research into improving care after hospital discharge within HIV programmes, with a focus on developing practical solutions informed by the experiences of patients, […]
AIDS 2026: Evidence, Partnership and Community in Action
From advanced HIV disease to community-led research, Aurum and IMPAACT4HIV brought evidence, expertise and lived experience to AIDS 2026 in Rio de Janeiro. The IMPAACT4HIV Satellite Session was a key moment of the week, bringing partners, policymakers, researchers and community leaders together to ask an important question: How do we build advanced HIV disease care […]
Across South Africa’s North West province, Aurum’s Youth Care Clubs (YCCs) are creating safe, youth-led spaces that restore confidence, build resilience, and ensure that young people living with HIV can access the care they need without fear, stigma, or judgement. Inside clinic rooms and community halls, adolescents gather each month to do far more than […]
Prof Geoffrey Setswe on the Impact of HIV Funding Cuts in South Africa
As the global HIV community gathered for AIDS 2026, questions around the sustainability of the HIV response are more urgent than ever. SABC News Specialist Health Reporter Zandile Myeza spoke to Prof Geoffrey Setswe, CEO of Aurum South Africa, about the impact of the withdrawal of PEPFAR funding on HIV programmes in South Africa and […]
Aurum at SA TB 2026: Bringing Evidence to the TB Response
TB remains one of South Africa’s most urgent health challenges. At the 9th SA TB Conference, Aurum researchers and experts joined partners from across the TB community to share evidence, challenge current approaches and explore what it will take to end TB. Under the conference theme Vuka: Let’s unite towards a TB-free world, Aurum contributed […]
World TB Month 2026: Putting Faces to the TB Response
We marked World TB Month under the theme “Led by Communities. Powered by Innovation.” Across our programmes, we used the month to put people, research and real-world impact at the centre of the TB conversation. TB Diagnostics Have a Face Our TB Diagnostics Have a Face campaign brought the human side of TB diagnosis into […]
A new generation of rapid TB diagnostics is set to reach 13 countries, bringing accurate testing closer to communities that have previously lacked access. Supported by the Children’s Investment Fund Foundation (CIFF) funded by The Global Fund and implemented on the ground by Aurum Institute, the initiative will deliver nearly three million fast, accurate TB […]
The Aurum Institute’s Biomedical Research Laboratory (BRL) in Tembisa has become the first laboratory within Aurum to receive accreditation from the South African National Accreditation System (SANAS) under the ISO 15189:2022 standard — the internationally recognised benchmark for quality and competence in medical laboratories. In practical terms, this means the laboratory has been independently assessed […]
SUPREME-SECURE launches call to improve maternal health.
SUPREME-SECURE is inviting manufacturers of blood pressure measuring devices to help expand access to home-based blood pressure monitoring for pregnant women through a new Request for Proposals (RFP) focused on validation, regulatory approval and market access in sub-Saharan Africa. Hypertensive disorders of pregnancy, particularly pre-eclampsia, remain among the leading direct causes of maternal death worldwide, […]
Prof Geoffrey Setswe to lead Aurum South Africa as CEO.
The Aurum Institute, a leading Africa-based global health organisation, today announced the appointment of Professor Geoffrey Setswe as Chief Executive Officer of Aurum Institute South Africa, effective 1 July 2026. Aurum Institute South Africa is the largest country entity within The Aurum Institute Group and plays a central role in the organisation’s research, health systems […]
The Aurum Institute USA is pleased to announce the appointment of Dr. Jirair Ratevosian, BA, BS, DrPH, to its Board of Directors effective July 1, 2026. Dr Ratevosian joins the Board at a pivotal time for global health and international development, bringing more than two decades of leadership experience across government, academia, philanthropy, multilateral institutions, […]
Towards culture-free sequencing of Mycobacterium tuberculosis: evaluating new targeted and whole-genome approaches for genotyping and drug resistance profiling
Iannucci I, Di Marco F, Moghaddasi K, Miotto P; *POR TB study group; Cabibbe AM, Cirillo DM
The Provision of Care for Patients with Tuberculosis and Diabetes Mellitus Multi-Morbidity in Addis Ababa, Ethiopia: An Analysis of Patients' Perspectives
Salato ST, Setswe KG
Int J Environ Res Public Health. 2026 Jul 18;23(7):925.
'Why should I start medication when I am not feeling sick?' A qualitative study of refusal, initiation, completion and discontinuation of tuberculosis preventive treatment among people living with HIV in sub-Saharan Africa
Tsope L, Chimoyi L, Kennar A, Rabothata I, Sisay S, Sithole K, et al.
Reported Effectiveness of a Text-Based Post-Operative Care Intervention After Voluntary Medical Male Circumcision (VMMC) to Improve Quality of Care and Adverse Events Identification in Sub-Saharan Africa: A Scoping Review
Potentials and challenges of next generation sequencing-guided individualized treatment for management of rifampicin-resistant tuberculosis - A qualitative study
Trang TPH, Barrenechea-Pulache A, De Wet K, Fanampe B, Charalambous S, Van Rie A
Sexual Behaviors and Psychosocial Health Among Men Who Have Sex with Men with and without Female Partners in Kenya: Baseline Findings from the Tatu Pamoja Study
Vu K, Mehta SD, Wahome E, van der Elst E, Mohamed K, Aloo T, et al.
Advancing national preparedness for the introduction of novel tuberculosis vaccines in South Africa: policy, evidence, and system readiness insights from a national workshop
Ndjeka N, Subrayen P, Hanekom WA, Jassat W, Luabeya AKK, Mkhondo N, et al.
Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial
Dawson R, Diacon AH, Variava E, Moloantoa T, Brumskine W, Ngwanto T, et al.
Lancet Infect Dis. 2026 May 29:S1473-3099(26)00143-X.
Safety of short-course weekly rifapentine and isoniazid (3HP) for TB preventive treatment at conception and during first trimester in women living with HIV: a secondary analysis of WHIP3TB trial
Investigation of correlates of protection against gonococcal infection by comparative immunoprofiling of responses in experimental and clinical studies
McKeand SA, Bencomo FR, Soc A, Jones RA, Thistlethwaite A, Gu Z, et al.
Whole genome sequencing precision medicine strategy to shorten treatment for rifampicin-resistant tuberculosis (SMARTT): a pragmatic, randomised, single-blind phase 4 trial
Van Rie A, Conceição EC, Ndebele F, Wells F, Paulse A, Mekonnen EG, et al.
Landovitz RJ, Pinedo Y, Hinestrosa F, Crofoot ……………
Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study. Clin Infect Dis. 2026 Mar 14:ciag171.
AS01B-, MF59-, and alum-based adjuvants and HIV vaccine immunogenicity: a post-hoc cross-protocol comparison of results from HVTN 100, 107, 120, and 702
Menezes F, Chen S, Grunenberg N, Malahleha M, Mngadi K, Muyoyeta M, et al.
Targeted and whole-genome sequencing for drug resistance and genetic relatedness inference of rifampicin-resistant Mycobacterium tuberculosis: an in-depth comparison
de Diego Fuertes M, Costa Conceição E, Wells F, Rennie V, Heupink T, Churchyard G, et al.
Risk factors for immunological sensitization to Mycobacterium tuberculosis and progression to incident TB disease among HIV-uninfected adults in a high burden setting
Mulenga H, Mendelsohn SC, Fiore-Gartland A, Penn-Nicholson A, Musvosvi M, Tameris M, et al.
A qualitative study assessing the acceptability of a multi-agent AI Chatbot for providing HIV and mental health support among men who have sex with men and transgender women in KwaZulu-Natal, South Africa
Humphries H, Msimango L, Tshawe Z, Gcelu N, Ferreira K, Pienaar J, et al.
Trans R Soc Trop Med Hyg. 2026 Feb 2;120(2):160-174.
Barriers and facilitators of implementing public-private mix approaches for active tuberculosis case finding and health insurance access in at-risk populations in Ghana: a qualitative study
Hayibor KM, Kenu E, Bandoh DA, Owusu-Arthur B, Odikro MA, Mensah GI, et al.
A Mixed-Method Evaluation of the Association Between Attitudes Toward Gender-Based Violence and Sexual Behaviors Among Adolescents and Young Adults in Rustenburg, South Africa
Makkan H, Mlotshwa M, Masibi P, Molefe T, Mthembu F, Maenetje P, et al.
Baseline determinants of adherence for drug-sensitive TB treatment in a South African prospective cohort: a focus on HIV infection and anti-retroviral therapy, clinical care access, and TB stigma
Steulet A, Hippner P, Maraba N, Jennings L, Rabothata I, Mukora R, et al.
World Health Organization-Recommended Periodic Presumptive Treatment Versus Doxycycline Post-Exposure Prophylaxis for Sexually Transmitted Infection Control Among Men Who Have Sex With Men in Kenya: Protocol for a Randomized Controlled Trial
Graham SM, Otieno FO, Kimani J, Barrientos A, Soge OO, Sharma M, et al.
A Four-Item Risk Score to Target Acute HIV Infection Testing Among Men Who Have Sex With Men in Indonesia: Development and Validation in the INTERACT Prospective Cohort
Lazarus G, Kawi NH, Luis H, Rahmawati DP, Sihotang EP, Oktaviani M, et al.
Qualitative Identification of HIV Care Engagement Challenges and Preferences for Differentiated Care Service Delivery Models Post-Incarceration in South Africa
Mqedlana-Ntombela N, Mabuto T, Owczarzak J, Charalambous S, Hoffmann CJ
Randomised Trial of a Single Dose of Ad26.COV2.S, BNT162b2 or SARS-CoV-2-rS-PN in Previously Vaccinated and Unvaccinated Adults Living with and without HIV in South Africa: Safety and Immunogenicity
Rates and Risk Factors for On-Treatment Mortality Among a Cohort of Adults Treated for Drug-Sensitive Tuberculosis: Analysis of Data From the Adherence Support Coalition to End Tuberculosis Consortium in Five Countries
Tadesse AW, Maraba N, Alacapa J, Gamazina K, Dube T, Onjare B, et al.
Trop Med Int Health. 2025 Oct 3. Epub ahead of print.
Shewamene Z, Goscé L, van Rest J, Madden N, Charalambous S, van Kalmthout K, Bedru A, Letta T, Jerene D, Fielding KL
Tadesse AW, Sahile M, Foster N, McQuaid CF, ....
Digital adherence technology interventions to reduce poor end-of-treatment outcomes and recurrence among adults with drug-sensitive tuberculosis in Ethiopia: a three-arm, pragmatic, cluster-randomised, controlled trial. Lancet Digit Health. 2025 Sep 29:100895.
Uptake of a Case Management Intervention for Continuity of Human Immunodeficiency Virus Treatment Among Individuals Released From Incarceration Living With HIV in South Africa
Ndini P, Mabuto T, Charalambous S, Chimoyi L, Wahome E, Hoffmann CJ, Ndlovu N
Protecting households on exposure to newly diagnosed index multidrug-resistant tuberculosis patients: Study protocol for the PHOENIx phase 3 clinical trial
Kendall MA, Hughes MD, Kim S, Aaron LA, Naini L, Suryavanshi N, et al.
"If we lose it, we are worried": Individual and provider level perceptions towards weight change among people living with HIV who undergo TB screening in routine health care settings in Gauteng Province, South Africa
Dube TN, Mboniswa F, Qwana SE, Charalambous S, Ndlovu N, Grant AD, et al.
Evaluation of QIAreach QuantiFERON-TB lateral-flow nanoparticle fluorescence assay for TB infection diagnosis among TB household contacts in three high-burden settings
Ntshiqa T, Fasanmi A, Nagudi J, Tsope L, Copas A, Stender S, et al.
The treatment gap and the HIV care continuum for cisgender men who have sex with men in three South African cities: Findings from a biobehavioural survey, 2019
Giovenco D, Mabuto T, Manyuchi A, Savva H, McIntyre A, Puren A, et al.
PLOS Glob Public Health. 2025 Sep 2;5(9):e0004874.
Assessment of the Syndemic Relationship Between Individual, Social, and Structural Determinants of Tuberculosis Among People Living in Johannesburg, South Africa
Tanyanyiwa FT, Van Wyk RH, Setswe KG
Int J Environ Res Public Health. 2025 Aug 14;22(8):1272.
An evaluation of a choice architecture-based intervention on prescribing of TB preventive treatment to people living with HIV in southern Africa (the CAT study): a cluster-randomised trial
Shearer K, Nonyane BAS, Mulder C, Kaonga E, Nyirenda R, Mbendera K, et al.
Effectiveness of a Home-based Approach to Child Contact Investigation and TPT Management by Community Health Workers in Ethiopia: A Pragmatic Cluster-randomized Trial. Clin Infect Dis. 2025 May 16: ciaf203.
Simultaneous initiation of dolutegravir-based antiretroviral therapy and once-weekly rifapentine and isoniazid for tuberculosis prevention in antiretroviral-naive people with HIV: an open-label, non-randomised, phase 1/2 trial
Weld ED, Beattie T, Moodley J, Mapendere M, Salles I, Solans BP, et al.
Finding the balance between rigour and relevance: implementing adaptations to the implementation of a pragmatic randomised controlled trial of a two-way texting intervention for voluntary medical male circumcision in South Africa
Setswe G, Day S, Ndebele F, Pienaar J, Ncube V, Feldacker C
Effect of the vaginal live biotherapeutic LACTIN-V (Lactobacillus crispatus CTV-05) on vaginal microbiota and genital tract inflammation among women at high risk of HIV acquisition in South Africa: a phase 2, randomised, placebo-controlled trial
Hemmerling A, Mitchell CM, Demby S, Gebremichael M, Elsherbini J, Xu J, et al.
Lancet Microbe. 2025 Apr 3:101037. Epub ahead of print.
Zwane Z, Cox S, Deaton C, Ebrahimi R, Wong P, Singh R, Brown LB, Carter CC, Das M, Baeten JM, Ogbuagu O; PURPOSE 2 Study Team
Kelley CF, Acevedo-Quiñones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, …………
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. N Engl J Med. 2025 Apr 3;392(13):1261-1276. (Purpose 2 Study Team – I Shibambo, K Mngadi).
Acceptability of the live biotherapeutic LACTIN-V (Lactobacillus crispatus CTV-05) among young women at high risk of HIV acquisition in South Africa: data from the phase 2 placebo-controlled trial
Hemmerling A, Govender V, Dong K, Dong M, Pillay S, Ndung'u T, et al.
Impact of COVID-19 on the HIV Treatment Outcomes Among Men Who Have Sex with Men in South Africa After the Implementation of a Differentiated Service Delivery Model: An Interrupted Time Series Analysis
Sebati B, Phalane E, Shiferaw YA, Pienaar J, Furamera S, Phaswana-Mafuya RN
Int J Environ Res Public Health. 2025 Mar 19;22(3):452.
Borges ÁH, Russell M, Tait D, Scriba TJ, Nemes E, Skallerup P, et al.
Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Infect Dis. 2025 Mar 5:S1473-3099(24)00814-4.
Understanding the occurrence and determinants of catastrophic costs of rifampicin resistant tuberculosis in South Africa to inform a patient-centered care program
Wang Z, Ndebele F, Sibeko ZR, Bohlela S, Segwaba P, Fanampe B, et al.
Garrett N, Tapley A, Hudson A, Dadabhai S, Zhang B, Mgodi NM, et al.
Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study. EClinicalMedicine. 2025 Jan 20; 80:103054.
Corrigendum to 'Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study'
Kenny A, van Duijn J, Dintwe O, Heptinstall J, Burnham R, ……………….., et al.
A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials
Moodie Z, Li SS, Giorgi EE, Williams LD, Dintwe O, Carpp LN, et al.
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial
Heinrich N, de Jager V, Dreisbach J, Gross-Demel P, Schultz S, Gerbach S, et al.
Effectiveness of the primary Bacillus Calmette-Guérin vaccine against the risk of Mycobacterium tuberculosis infection and tuberculosis disease: a meta-analysis of individual participant data
Assessing Vaccine Confidence Using the Vaccine Hesitancy Scale Among Adolescent Girls and Young Women at Risk of HIV Acquisition Living in Uganda, Zambia, and South Africa
Kyakuwa N, Ssetaala A, Price MA, Nanvubya A, Abyesiza JM, Basalirwa G, et al.
"They recognize me as a doctor": A peer mobilisation training programme to promote oral HIV self-testing and referral for acute HIV infection screening among gay and bisexual men and transgender women in coastal Kenya, an exploratory study
Palmer S, Dijkstra M, Kigoro A, Mohamed K, Mukuria N, Mahmoud S, et al.
Using participatory methods to develop a narrative intervention to alleviate distress in children hospitalised with TB in South Africa: The DIMPle project
October CD, Baloyi DP, Viljoen L, Raad R, Wademan DT, Palmer M, et al.
The effectiveness, cost-effectiveness, budget impact, and return on investment of scaling up tuberculosis screening and preventive treatment in Brazil, Georgia, Kenya, and South Africa: a modelling study
Vesga JF, Mohamed MS, Shandal M, Jabbour E, Lomtadze N, Kubjane M, et al.
Treatment completion and challenges in rolling out 12-dose weekly rifapentine plus isoniazid to prevent tuberculosis among people living with HIV and pediatric household contacts in Brazil
Salles I, Garcia de Oliveira J, Brito de Souza A, Cohn S, Spener-Gomes R, Dourado de Andrade S, et al.
Strengthening evidence for text-based telehealth in post-operative care: A pragmatic study of the reach and effectiveness of two-way, text-based follow-up after voluntary medical male circumcision in South Africa
Feldacker C, Fabens I, Dong TQ, Moyo K, Makhele C, Phohole M, et al.
Community and Universal Testing for TB among close contacts of microbiologically confirmed pulmonary TB patients in two high TB burden countries: a protocol for a pragmatic cluster-randomised control trial
Moyo M, Ntshiqa T, Hamada Y, …Kubeka G, Tsope L, Mukora R, et al.
Epidemiological factors associated with immunological resistance in household contacts exposed to active tuberculosis in South Africa: A logistic regression analysis
Maenetje N, Oladimeji M, Mlotshwa M, Hoft D, Lindan C, Wallis R, et al.
Adaptation of Inuka coaching problem-solving therapy to support mental health and HIV medication adherence among status-neutral men who have sex with men in South Africa
Tsope L, van der Elst EM, Pienaar J, Denousse C, Mabena M, Komane P, et al.
One year on - the long-term impact of COVID-19 pandemic and government restrictions on the health-seeking behaviour, financial security and mental health of TB survivors
Jinga N, Hirasen K, Ivanova O, Rachow A, Charalambous S, Lönnroth K, et al.
Engagement With Digital Adherence Technologies as Measures of Intervention Fidelity Among Adults With Drug-Susceptible Tuberculosis and Health Care Providers: Descriptive Analysis Using Data From Cluster-Randomized Trials in Five Countries
Alacapa J, Tadesse AW, Deyanova N, Dube T, Mganga A, Powers R, et al.
Is South Africa ready for point-of-care, non-sputum tests for TB diagnosis? An assessment of end-user perceptions on a novel urine test and tongue swab for TB testing
Mqedlana-Ntombela N, Fargnoli V, Charalambous S, Velen K, Shilton S, Chihota V
Analytical treatment interruption among women with HIV in Southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical data
Karuna S, Laher F, Dadabhai S, Yu PC, Grove D, Orrell C, et al.
When evidence is not enough: A qualitative exploration of healthcare workers' perspectives on expansion of two-way texting (2wT) for post- circumcision follow-up in South Africa
Fabens I, Makhele C, Igaba N, Moyo K, Ndebele F, Pienaar J, et al.
Provider perspectives on empirical antibiotic treatment for tuberculosis-like symptoms in South Africa's private general practice sector: A qualitative study in two cities
Chikovore J, Boffa J, Moyo S, Mak A, Gavu Z, Salomon A, et al.
Risk factors associated with TB infection among household contacts of microbiologically confirmed pulmonary TB patients in three high TB burden countries
Ntshiqa T, Nagudi J, Hamada Y, Copas A, Stender S, Sabi I, et al.
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial
Minja LT, van der Feltz I, Manyama C, Mpagama S, Mhimbira F, Noreña I, et al.
Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial
Heinrich N, Manyama C, Koele SE, Mpagama S, Mhimbira F, Sebe M, et al.
Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trials
White RG, Churchyard GJ, Horton KC, Fiore-Gartland A, Behr MA, Clark RA, et al.
Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01(E-4) in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial
Dagnew AF, Han LL, Naidoo K, Fairlie L, Innes JC, Middelkoop K, et al.
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB
Koele SE, Stoycheva K, Mtweve C, Manyama C, Mpagama S, Mhimbira F, et al.
Process Evaluation of Pragmatic Cluster-Randomized Trials of Digital Adherence Technologies for Tuberculosis Treatment Support: A Mixed-Method Study in Five Countries
“Time to Change”: To What Extent Could Non-Sputum Sampling Accelerate the Fight Against Tuberculosis—A Qualitative Study Among End-Users. Trop Med and Infect Dis
Fargnoli V, Hanh HTM, Hoang LN, Mahesh A, Mqedlana-Ntombela N, Xavier J, et al.
Knowledge and reporting of adverse events following childhood immunization (AEFI) among health workers and caregivers at Mengo Hospital (2021), Kampala, Uganda: A mixed-methods study
Watyaba B, Chimoyi L, Knezevic I, Malande OO, Kalutte H, Bazira H, et al.
Treatment adherence and clinical outcomes amongst in people with drug-susceptible tuberculosis using medication monitor and differentiated care approach compared with standard of care in South Africa: a cluster randomized trial
Charalambous S, Maraba N, Jennings L, Rabothata I, Cogill D, Mukora R, et al.